Showing results (681-690 of 870) with videos related to

Sort By:
Pageof 87
European Journal of Neurology|September 10, 2022
Signs and symptoms of COVID-19 in patients with multiple sclerosisIrene Schiavetti, Luca Carmisciano, Marta Ponzano, et al.
International Journal of Medical Informatics|June 10, 2026
Web-based family-reported outcomes to assess family functioning in multiple sclerosis: an Italian multicenter digital surveyLuigi Lavorgna, Giuseppina Miele, Marta Ponzano, et al.
Scientific Reports|February 5, 2025
Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathiesOliver C Kiersnowski, Pietro Mattioli, Lucia Argenti, et al.
Muscle & Nerve|January 25, 2019
Revised upper limb module for spinal muscular atrophy: 12 month changesMaria Carmela Pera, Giorgia Coratti, Elena S Mazzone, et al.
European Journal of Neurology|June 22, 2026
Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO TrialPatrick Vermersch, Ralph H B Benedict, Bart Van Wijmeersch, et al.
Neurology|June 17, 2016
Assessing response to interferon-β in a multicenter dataset of patients with MSMaria Pia Sormani, Claudio Gasperini, Marzia Romeo, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 10, 2021
COVID-19 Severity in Multiple Sclerosis: Putting Data Into ContextMaria Pia Sormani, Irene Schiavetti, Luca Carmisciano, et al.
Neurobiology of Aging|June 18, 2019
Lifespan normative data on rates of brain volume changesMarco Battaglini, Giordano Gentile, Ludovico Luchetti, et al.
Annals of Medicine|April 13, 2023
External validation of unsupervised COVID-19 clinical phenotypes and their prognostic impactDaniele Roberto Giacobbe, Emilio Di Maria, Alberto Stefano Tagliafico, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trialPeter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, et al.
Pageof 87